Kymera Therapeutics Inc

KYMR

Company Profile

  • Business description

    Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients’ lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

  • Contact

    500 North Beacon Street
    4th Floor
    WatertownMA02472
    USA

    T: +1 857 285-5300

    E: [email protected]

    https://www.kymeratx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    225

Stocks News & Analysis

stocks

Is this ASX share a value trap or bargain?

Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks

Goldman Sachs Earnings: Valuations remain stretched

We raise our fair value estimate for Goldman Sachs stock.
stocks

Major ASX listed miners overvalued

We’ve adjusted our fair values after updating our commodity price assumptions.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,194.9012.40-0.13%
CAC 408,112.02146.92-1.78%
DAX 4024,959.06338.07-1.34%
Dow JONES (US)49,359.3383.11-0.17%
FTSE 10010,195.3539.94-0.39%
HKSE26,563.90281.06-1.05%
NASDAQ23,515.3914.63-0.06%
Nikkei 22553,583.57352.60-0.65%
NZX 50 Index13,580.29137.81-1.00%
S&P 5006,940.014.46-0.06%
S&P/ASX 2008,874.509.20-0.10%
SSE Composite Index4,114.0012.090.29%

Market Movers